Sign In
Buy NAD
$11.71
+0.0100 (+0.0855%)
At Close: Jul 31, 2026
CEFs Are Becoming Less Appealing For Income Investors
01:15pm, Tuesday, 09'th Sep 2025
The investment case for closed-end funds (CEFs) is weak now due to tight discounts, high leverage costs, and expensive underlying assets. Most CEFs do not deliver sustainable alpha, and lower-fee acti
NAD: Municipal CEF Suppressed By Higher Interest Rates
07:49am, Sunday, 10'th Aug 2025
NAD offers a high 8% tax-exempt yield, but its share price and NAV have struggled, amid high interest rates and aggressive leverage. The fund's discount to NAV is historically narrow, making current a
Unleveraged Options In The Tax-Exempt Sector
04:14am, Friday, 25'th Jul 2025
Fund-level leverage is only attractive when carry or capital gains potential is high; current tight spreads and an inverted yield curve make it less appealing. For tax-exempt CEFs, higher yields often
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the
A $7-Trillion Cash Wave Is About To Flood Dividend Stocks
11:32am, Wednesday, 25'th Jun 2025
Stocks—especially dividend stocks—have every reason to shoot higher from here. In fact, they have 7 trillion reasons.
Need Almost $1100 per Month in Tax-Free Income? Invest in 8 Municipal Bond ETFs
08:12am, Friday, 20'th Jun 2025
One of the only downsides to passive income from stocks and bonds is that the revenue generated from those investments is subject to federal and state income tax.
NAD: A Proxy For Investment Grade Corporate Exposure
11:47am, Thursday, 29'th May 2025
The credit cycle is arguably deteriorating. Thus, we see investors moving out of corporate credit and into Municipal bonds with hybrid general obligation and revenue exposure. Nuveen Quality Muni Inco
NAD: I See This Fund Pushing Higher Along With The Municipal Sector
01:56am, Wednesday, 30'th Apr 2025
Evaluating Nuveen Quality Muni Income Fund as an investment due to its current market price and high yield above 8%. NAD's recent price weakness in 2025 appears overdone, presenting a potential buying
Forget Growth: 5 Big Safe Yields Worth Considering
02:00am, Thursday, 13'th Mar 2025
The stock market has been ugly (particularly growth stocks), and it could get much worse. Thankfully, however, there is another way. Income investing focuses on big, steady dividend and interest payme
Want Over $1000 per Month in Tax-Free Income? Buy These 8 Municipal Bond ETFs
07:41am, Monday, 10'th Feb 2025
One of the only downsides to passive income from stocks and bonds is that the revenue generated from those investments is subject to federal and state income tax.
Hydreight Technologies Expands Telehealth Offerings with Launch of NAD+ Therapy on VSDHOne Platform
07:30am, Wednesday, 05'th Feb 2025
New NAD+ Patch, Injection, and Nasal Spray Now Available for Personalized Wellness and Longevity Solutions New NAD+ Patch, Injection, and Nasal Spray Now Available for Personalized Wellness and Longev
This Tax-Free 7.8% Dividend Could Soar In 2025
09:30am, Wednesday, 08'th Jan 2025
If you were taking a break from your family on Christmas Day, you may have caught my article on how Jay Powell's recent “hawkish cut” is set to light a fire under high-yielding (and tax-free!) mun
CEF Weekly Review: Muni ROC Is Mountain High
10:05pm, Saturday, 28'th Dec 2024
We review the CEF market valuation and performance through the third week of December and highlight recent market action. All CEF sectors declined this week due to a more hawkish Fed, with most discou
NAD Vs. NXP Revisited: Time To Delever
01:07am, Tuesday, 03'rd Dec 2024
Nuveen Quality Municipal Income Fund distributions are only about 52% covered by investment income. NAD is also leveraged, which helped returns in 2024 but may not be an advantage going forward as rat
In a challenge brought by competitor PIM Brands, Inc., BBB National Programs' National Advertising Division recommended that General Mills, Inc. discontinue or modify certain express and implied claim
